Rocuronium + Rocuronium
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Laparoscopic Renal Surgery
Conditions
Laparoscopic Renal Surgery, Laparoscopy, Muscle Relaxation
Trial Timeline
Jul 1, 2014 → Jan 1, 2015
NCT ID
NCT02185339About Rocuronium + Rocuronium
Rocuronium + Rocuronium is a approved stage product being developed by Merck for Laparoscopic Renal Surgery. The current trial status is completed. This product is registered under clinical trial identifier NCT02185339. Target conditions include Laparoscopic Renal Surgery, Laparoscopy, Muscle Relaxation.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02185339 | Approved | Completed |
Competing Products
7 competing products in Laparoscopic Renal Surgery
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pudexacianinium chloride | Astellas Pharma | Phase 2 | 52 |
| SHR0410 Injection + SHR0410 Injection + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Entereg + Entereg + placebo | Merck | Phase 2 | 52 |
| Rocuronium IV bolus 0.1 mg/kg guided by TOF that must remain between 1-3 during surgery + Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2 | Merck | Approved | 85 |
| etoricoxib 120 mg | Merck | Approved | 85 |
| placebo + valdecoxib + valdecoxib | Pfizer | Phase 3 | 76 |
| N1539 + N1539 + N1539 + Ketorolac Tromethamine + Placebo | Alkermes | Phase 3 | 74 |